Major Insurance Changes Are Coming for Weight Loss Drugs. Here’s How It Could Affect Patients

GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials

Glucagon-like peptide-1 (GLP-1) receptor agonists were recently approved for obesity treatment in children 12–17 years by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). However, their effectiveness in younger pediatric patients remains uncertain. We systematically searched PubMed, Embase and Cochrane for randomized controlled trials (RCTs) comparing GLP-1 receptor agonists versus. placebo in children and ado…

GLP-1s a good start to treat obesity, but patients need nutritional counseling and more, experts say

New advisory endorsed by major medical groups outlines state of health care around GLP-1 drugs and obesity treatment.

The Government Crackdown on Off-Brand Ozempic Has Begun. Here’s What That Means for You.

New rules are reshaping the telehealth market for GLP-1s like Ozempic or Wegovy—potentially impacting access to these medications for millions of people. Here’s what to know going forward.

I'm Taking A GLP-1 Drug & Terrified It'll Mess Up My Daughters' Body Image

Duane Rieder/Getty ImagesAt my annual check-up with my OB-GYN, I brought up how frustrated I was with my weight. She responded that I had actually lost a couple of pounds since my last visit and was now back at my December 2022 weight, thinking that would comfort me.Instead, I burst into tears. December 2022 was six weeks after my second daughter was born.In the two and a half years since she arrived, I’ve been good about strength training two t…

MyStart Health Reflects Growing Demand for Accessible Weight Wellness Platforms

The global weight loss industry is booming, expected to surpass $300 billion by 2027; however, much of it is saturated with fad diets, unverified supplements, and unsustainable protocols. MyStart Health is disrupting this cycle by offering access to FDA-approved GLP-1-based treatments through an entirely virtual healthcare model.

Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share

Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.